An open-label, Phase I study to assess safety, tolerability, radiation dosimetry, and imaging properties of 89Zr-labelled girentuximab (89Zr-girentuximab) for in vivo detection of clear cell renal carcinoma (CCRC) by positron emission tomography (PET) using different PET imaging methodologies.
- Conditions
- clear cell renal carcinomakidney cancer10038364
- Registration Number
- NL-OMON44583
- Lead Sponsor
- TELIX International Pty. Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 10
All patients must meet all of the following criteria:;- Written informed consent
- Male or female >50 years of age
- Clinical suspicion of CCRC, based on incidental imaging evidence of a renal mass, requiring further diagnostic work-up (incidentalomas), or patients with established diagnosis of CCRC requiring staging
- Life expectancy of at least 6 months
- Consent to practise contraception until end of study (7 days after 89Zr-girentuximab injection)
A patient will be excluded from participation in the trial if one or more of the following criteria are met:;- Known hypersensitivity to girentuximab
- Known uncontrolled hyperthyreoidism
- Exposure to any experimental diagnostic or therapeutic drug within 30 days from the date of planned administration of 89Zr-girentuximab
- Exposure to any radiopharmaceutical within 30 days (corresponding to 8 half-lives of 89Zr) prior to the administration of 89Zr-girentuximab.
- Ongoing toxicity grade 2 from previous standard or investigational therapies (Common Terminology Criteria for Adverse Events [CTCAE] version 4.03)
- Planned (for the period between injection of 89Zr-girentuximab and imaging) antineoplastic therapies
- Established renal cell carcinomas of other histological entities than CCRC
- Known brain metastases
- Serious non-malignant disease (e.g. psychiatric, infectious, autoimmune or metabolic), that may interfere with the objectives of the study or with the safety or compliance of the subject, as judged by the investigator
- Pregnant or breast-feeding women. Female patients of childbearing potential or male patients with female partners of childbearing potential, unless willing to practice full and true sexual abstinence or being surgically/permanently sterile or with a history of hysterectomy for women, not willing to practice effective contraception by using: a non-oral, injected or implanted non-oestrogen progesterone based hormonal method, male condom, vaginal diaphragm, cervical cap, intrauterine device, during the study period and within a period of 28 days (corresponding to 8 half-lives of 89Zr) after receiving study drug.
11. Subjects not able to declare meaningful informed consent on their own (e.g. with legal guardian for mental disorders)
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The primary objective of this study will be to evaluate clinical safety and<br /><br>tolerability of 89Zr-girentuximab.</p><br>
- Secondary Outcome Measures
Name Time Method <p>- To determine the whole body radiation dosimetry of 89Zr-girentuximab in<br /><br>patients with suspected CCRC<br /><br>- To assess diagnostic image quality of 89Zr-girentuximab using a<br /><br>time-of-flight PET (TOF-PET) compared a conventional PET (C-PET reconstruction)<br /><br>- To assess diagnostic image quality of 89Zr-girentuximab using a 37 MBq (1<br /><br>mCi) activity dose and different acquisition durations (5, 10, 15 vs. 20 min)<br /><br>- To establish activity dose and recommended acquisition modalities for further<br /><br>clinical development</p><br>